Nataliya V. Uboha, MD, PhD

Experts discuss specific biomarkers or clinical features that would prompt earlier consideration of trastuzumab deruxtecan or other HER2-directed therapies.

Experts discuss the factors supporting the choice of trastuzumab deruxtecan following disease progression and its mechanism of action in addressing resistance to prior HER2-targeted therapy and provide insights on the updated analysis from the DESTINY-Gastric02 Trial.

Experts discuss the PD-L1 combined positive score (CPS) and its influence on treatment decisions as well as the clinical significance of a high CPS in guiding the use of immune checkpoint inhibitors such as pembrolizumab in HER2-positive gastric cancer.

Experts discuss Megan’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment strategies and challenges.

Experts discuss how to approach prognosis and treatment goals with a patient, considering their family history of gastric cancer and advanced-stage disease.

Experts discuss how biomarker testing results should be reassessed or expanded upon disease progression and how they guide the selection of second-line therapies or clinical trial enrollment.

Experts discuss the relevance of PD-L1 CPS in predicting immunotherapy efficacy, other complementary biomarkers, the benefits of adding nivolumab to a FOLFOX regimen, and how the CheckMate 649 trial and its recent 5-year update have influenced the use of nivolumab in combination with chemotherapy for advanced gastric and gastroesophageal adenocarcinomas.

Experts discuss the role of reflex testing in ensuring accurate and timely treatment selection, the challenges it may present, and how it can be integrated with next-generation sequencing (NGS) to provide a comprehensive molecular profile while minimizing delays.

Experts discuss frontline treatment options for advanced upper gastric adenocarcinoma, molecular testing methods, challenges encountered, and how test results influence the choice of systemic therapy for patients.

Experts discuss Robert’s journey with HER2-positive upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.